Equity Details
Price & Market Data
Price: $6.54
Daily Change: +$0.33 / 5.05%
Daily Range: $6.12 - $6.55
Market Cap: $40,037,800
Daily Volume: 94,946
Performance Metrics
1 Week: 1.89%
1 Month: -25.12%
3 Months: -9.89%
6 Months: -8.49%
1 Year: 13.91%
YTD: -30.58%
About Aligos Therapeutics, Inc. (ALGS)
Discover the investment profile of Aligos Therapeutics, Inc. (ALGS). With a price of 6.54, and a daily change of +$0.33 / 5.05%. Market cap: 40,037,800. Performance figures include YTD and 52-week returns.
Company Details
Employees: 82
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.